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Cancer survivorship research includes the study of physical, psychosocial, and economic consequences of cancer diagnosis and
treatment among pediatric and adult cancer survivors. Historically, the majority of cancer survivorship studies were from the
United States, but survivorship issues are increasingly being addressed in other developed countries. Cross-cultural studies
remain, however, scarce. The degree to which knowledge attained may or may not be transferred across cultures, countries, or
regions is not known. Some important challenges for comparative research are therefore discussed in a cross-cultural perspective.
Several substantive and methodological challenges that complicate the execution of cross-cultural cancer survivorship research are
presented with examples and discussed to facilitate comparative research eﬀorts in the establishment of new survivorship cohorts
and in the planning and implementation of survivorship studies. Comparative research is one key to understanding the nature
of cancer survivorship, distinguishing modiﬁable from nonmodiﬁable factors at individual, hospital, societal, and system levels
and may thus guide appropriate interventions. Lastly, suggested future courses of action within the ﬁeld of comparative cancer
survivorship research are provided.
1.Introduction
The emerging discipline of cancer survivorship research
includes the study of the consequences of cancer diagnosis
and its treatment among children and adults who have
experienced cancer [1]. While the United States (USA)
has conducted the majority of research on adult cancer
survivorship [2–6], the United Kingdom and Canada have
conducted large-scale cohort studies of childhood cancer
survivorship [7, 8]. As more countries are beginning to
address issues related to adult survivorship [9–20], it will
be important to consider how transferrable ﬁndings will be
across cultures and nations. Identifying generalizable and
nongeneralizable research among cultures will hasten what
we learn about cancer survivorship. This essay presents an
overview of cancer survivorship research and its challenges
and discusses in detail three examples of pronounced cross-
cultural challenges currently facing the ﬁeld. Finally, future
courses of action within the ﬁeld of comparative cancer
survivorship research are suggested.
2. Cancer SurvivorshipResearch
According to the US Institute of Medicine, cancer sur-
vivorship research encompasses the physical, psychosocial,
and economic consequences of cancer diagnosis and its
treatment among both pediatric and adult survivors of
cancer [1]. It seeks to “identify, examine, prevent, and
control adverse cancer- and treatment-related outcomes”
and to “provide a knowledge base regarding optimal follow-
up care and surveillance of cancer survivors” [1]. Lastly,
cancer survivorship research aspires to “optimize health after
cancer treatment”, seeking to promote healthy lifestyles and
behaviors. A cancer survivor is a person diagnosed with
cancer, current or past, who is still living [1]. Originally,
the medical community limited the term to denote persons2 Journal of Cancer Epidemiology
who remained alive and disease-free for a minimum of ﬁve
years, thus reﬂecting “cure.” Today’s cancer survivors may be
disease-free or not and may experience no, minor or major
short- or long-term eﬀects such as pain, sexual dysfunction,
second cancers, or poor quality of life from cancer illness
and/or treatment. Cancer survivorship denotes the phase
following primary treatment until end-of-life care or death.
Family members and caregivers may also be impacted by
the survivorship experience and are therefore included in
the survivorship deﬁnition, as are their processes related to
coping and/or grief [1, 5].
3.Scope ofToday’s Research
Cancer is one of the most common serious illnesses in
the developed world today, and between one in three and
o n ei nt w op e o p l ec a nb ee x p e c t e dt ob ed i a g n o s e dw i t h
cancer during their lifetime [21]. Cancer incidence increases
with age and is consequently rising in societies where
life expectancy is increasing. Concurrently, the number of
cancer cases is increasing due to cancer screening and
improved diagnostic tests, population growth, and changes
in underlying risk factors, such as environmental exposures,
obesity, and physical inactivity [1, 5, 21]. At the same time,
prognosis is improving for most cancers, and the overall
ﬁve-year relative survival after cancer is above 60% in most
developed countries due to early detection and improved
treatment [5, 21]. Europe has the highest number of cancer
survivors—close to 14 million, while there are about 12
million in Canada and the USA, about 8 million in South-
Eastern Asia, but only about 1 million in Oceania [21,
22]. This results in an estimated population of more than
35 million cancer survivors in the developed world alone,
corresponding to a population prevalence of about 3.5%.
The absolute number of cancer survivors is predicted to
increase nearly threefold over the next few decades, while the
number of cancer deaths is expected to double [21]. This
dramatic increase will have profound implications for the
individuals directly aﬀe c t e db yc a n c e ra n df o rs o c i e t i e sw h o
attend to their needs.
Cancer incidence and cause-of-death registration is
essential for identifying cancer survivors and for under-
standing the complex interplay. In many parts of the
developing world (e.g., most of Africa) resources for cancer
registration are not available [21]. Less than 20% of the
world’spopulationiscoveredbycancerregistriesandaround
30% by mortality registration [22], and the total number
of cancer survivors in the world is thus unknown. Research
on cancer survivorship is currently primarily undertaken in
countries with adequate cancer surveillance and suﬃcient
resources available to care for persons after a diagnosis has
been made [23].
Cancer survivorship research is currently conducted in
many ways, reﬂecting the complexities of the subject matter.
Like in other areas of health research data, data may be
collected prospectively [12] or retrospectively [24], and both
objective [25]a n ds u b j e c t i v e[ 10, 24] measures of exposures
and outcomes are relevant. The data sources span from
administrative records collected for other purposes such as
billing, to hospital, state and national cancer registry infor-
mation[11,12,26],clinicaltrials[27,28],aswellasinforma-
tionfromquestionnaires,interviews,orobservation[12,18].
In certain instances, more precise answers and further tests
may be required from subjects, including biological samples
(e.g., blood, urine, saliva) or physical stress tests or tests to
measure cognitive performance [29, 30], as well as diﬀerent
imaging techniques [31]. The majority of studies to date
have included only cancer survivors, but some questions are
impossible to answer without noncancer comparison groups
[10, 19, 25]. Essential components of cancer survivorship
research are the study of short-term, long-term, and late
organic and somatic eﬀects following cancer, treatment,
and cancer control interventions. The most commonly
reported long- and short-term physical complaints after
cancer are pain, digestive problems, neuropathies in the
extremities, cardiovascular problems, immune deﬁciency,
anemia, lymphedema, impaired vision due to cataracts,
impaired mobility, and fatigue[10,32].Researchhasfocused
on adverse eﬀects of cancer treatment on cognitive func-
tioning such as memory, attention, and concentration [33].
Cancer has also been reported to aﬀect psychological health
by increasing depression and anxiety [34]. A relatively new
avenue of research focuses on the economic and legal issues,
particularly the economic sequelae of cancer and cancer
treatment on individuals, families, and societies [15, 35, 36].
Cancer survivorship research also includes the promotion
of healthy lifestyles and behaviors studying the eﬀects of
interventions to reduce smoking, increase physical ﬁtness,
and reduce weight [37]. Beneﬁts of having survived cancer
have been identiﬁed through research, that is, posttraumatic
growth [24, 38]. Research on the role of families on
survivors’ health-related and psychosocial outcomes as well
as cancer survivorship’s impact on health and wellbeing
on family units, members, and caregivers is also emerging
[12, 39]. Recurrence and second primary cancers are of
particular concern [26]. Lastly, issues related to followup
care, access, and health care delivery are in the forefront,
with concerns about disparities related to poverty-related or
other sociodemographic patient characteristics, with a focus
on underserved populations [40–42].
4. CurrentChallenges
In cancer survivorship research, diverse information must be
collected and assessed over extended time periods and from
multiple sources, including the patient, family members,
caregivers, clinics, health care systems, and policy. This is
both practically and methodologically diﬃcult and costly
[6]. As is the case for many emerging research ﬁelds, the
challenges facing the ﬁeld of cancer survivorship research are
both substantive and methodological.
One important substantive challenge is to decide which
research questions to ask and what hypotheses to test in
this relatively new ﬁeld. Economic, legal, social, physical,
spiritual, emotional aspects, among others, have been identi-
ﬁed as content areas, but the relative importance placed on
each of these may vary between cultures because culturesJournal of Cancer Epidemiology 3
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Figure 1: An example of a substantive, a methodological, and a “shared” challenge.
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Figure 2: An illustration of possible groupings of cross-cultural challenges.
view and value illness, treatments, and caregiving diﬀerently
[20, 42, 43]. Are there common beliefs and attitudes among
diﬀerent cultures that can be studied to beneﬁt multiple
societies? What research questions and ﬁndings transfer
across societies? Which questions must be answered within
subcultures due to large contrasts between cultures or
societies? The answers to these questions impact on how
limited research funding can be distributed to optimize the
knowledge gained and thus augment cancer survivorship
care, cross-culturally.
Diﬀerent methodological challenges complicate cancer
survivorship research. As researchers we must learn how
to best measure the eﬀects of surviving cancer and how
to increase overall and subgroup research participation and
followup. To be eﬃcient we need to use existing data sources
while identifying new sources, and apply existing research
methods, while designing and testing new methods. Assess-
ing eﬀects from multiple sources and over time may call
for new and advanced research methods [44]. Researchers
withexpertise inresearchdesign, measurement,andanalyses
must be included. Finally, when considering design and
methods we must keep in the forefront the need to review
costs and beneﬁts as they relate to the generalizability of the
ﬁndings to diﬀerent populations.
The application of research ﬁndings to individuals and
s u b g r o u p sa c r o s sd i ﬀerent societies requires an understand-
ing of the substantive concerns of each culture and may
thus need to rely on study designs and methods that are
acceptable across cultures. These issues are also involved in
how one disseminates and uses the results to improve cancer
care across diﬀerent societies. Figure 1 exempliﬁes challenges
of either substantive or methodological character and also
provides an example of an area where there is overlap.
Thesubstantiveandmethodologicalchallengesdescribed
above may exist within one culture. As we proceed to
describe challenges across cultures, broadly deﬁned to
include diverse countries, societies, or groups within these
that share distinct features, matters become more compli-
cated. Diﬀerent cultures may face distinctive substantive
challenges. The relative importance of content areas may
diﬀer. Also methodological challenges may in part vary
across cultures, given diﬀerent infrastructures, data avail-
ability, and legal restrictions, whereas other methodological
challenges may have more general relevance. Across cultures,
one example of a substantive challenge could be “which
research questions and ﬁndings may be transferable from
one culture to another?”, as is shown on the left-hand
side in Figure 2. On the right-hand side in this ﬁgure,4 Journal of Cancer Epidemiology
an example of a methodological challenge could be “How
to make data comparable across studies to facilitate larger
samples and validity of results in universal versus speciﬁc
contexts?” An example of a challenge that cuts across this
categorization could be “How to design studies that may
generalize to diverse populations in diﬀerent societies?—
wheremorespeciﬁcallyone’sconcerncouldbehowtoensure
that the data collected represent similar constructs and
features across societies. Equally important is to recognize
what cultural aspects are so unique that they cannot be
compared across cultures.
There are three important challenges currently facing
cancer survivorship research. Each entails components of
both substantive and methodological issues, and we believe
that all need to be adequately addressed for cancer sur-
vivorship research to move forward. The ﬁrst challenge is
to determine which questions pertain across cultures. The
second challenge concerns how one may assure that what
is being measured is what one wants to measure across
cultures. It also encompasses how to extrapolate research
ﬁndings. Lastly, the challenge of securing nondiﬀerential
participation cross-culturally, initially, and during followup
will be addressed.
4.1. Challenge I: Determining Relevant Hypotheses and Out-
comes within and across Cultures. Certain research questions
are important to ask cross-culturally, whereas others may
be adequately addressed within (sub)cultures. Research
hypotheses, questions, and ﬁndings that generalize to other
societies and thus translate to larger/diverse populations
need not be replicated to the same extent as those that
are culturally speciﬁc. Distinguishing between unnecessary
and important replications is essential to minimize study
costs and ensure optimal outcomes for cancer survivors and
requires knowledge and insight into the diﬀerent cultures,
systems, and societies. Certain phenomena might need to
be studied in diﬀerent cultures and at various levels to
determine whether questions pertain cross-culturally and
across levels.
Examples of study questions that might be valid across
cultures include for instance the presence of short, long, and
late physical eﬀects following cancer and its treatment, as
there is little reason to believe that for instance drug side
eﬀects, late eﬀects of radiation, or the prevalence of second
cancers diﬀer markedly between cultures unless treatment
regimens have been substantially diﬀerent [10, 26, 32].
This was in part the case for pediatric cancer treatment
regimens in Europe and the USA a few decades ago [45],
a n dm a yh a v ec o n t r i b u t e dt od i ﬀerences in the type and
prevalence of somatic late eﬀects across regions. Perceptions
and implications of these late eﬀects, may, however, diﬀer
vastly between cultures, depending on health and welfare
systems, expectations and existing norms [16, 17, 46, 47].
A ne x a m p l eo faq u e s t i o nt h a ti sl e s sl i k e l yt ob ev a l i da c r o s s
cultures would be one that addresses economic sequelae of
cancer.Both the direct costs associated with becoming ill and
theindirectcostsassociatedwithillness-relatedworkabsence
are likely to vary as health insurance, followup care, access,
andhealthcaredeliverydiﬀeracrosscultures[15, 18, 48, 49].
Research on disparities in this area tends to show that
the least well oﬀ tend to fare the poorest, and poverty or
low socioeconomic resources thus becomes one possible
target where diﬀerential care or followup may be necessary
[40–42].
At the community level, one might ask whether results
from one hospital are likely to pertain to diﬀerent hospi-
tals, and similarly for regions and nations. For instance,
is research conducted in the USA relevant in European
countries and vice versa? Cultural diﬀerences in employment
behavior, perhaps driven by diﬀerences in health and welfare
systems, between the USA and Norway are highlighted in
this example where we compare employment after cancer.
Norwayprovidesuniversalaccesstocancercarewithoutcosts
to individuals, regardless of employment status and a fair
percentage stop working after their cancer diagnosis [48].
In the USA, employment rates remain relatively high after
cancer, perhaps in part because many who are ineligible for
Medicaid or Medicare have their health insurance linked
to their employment or the employment of their spouse,
frequently with large deductibles and copayments that can
forestall treatment and bankrupt families [50]. Further, US
breast cancer patients with health insurance tied to their
own employment have been found to be more likely to work
than those who are covered through their spouse [51]. This
would be an irrelevant study question in Norway and other
welfare states with universal health care. Likewise may cross-
cultural and international comparisons facilitate discussions
of the relative importance of organizational structures
across systems and disclose eﬀects that could be modiﬁed
within systems. The Aboriginal people in Australia have, for
instance, higher cancer mortality than the nonindigenous
population, and a study has identiﬁed transportation and
accommodation problems, travel and health care expenses,
removal from family, and lack of appropriate support
persons as important factors for treatment decisions and
access [42].
4.2. Challenge II: Determining Relevant Measurements and
Extrapolation of Findings at Diﬀerent Levels across Cultures.
The challenge of securing construct validity and thus con-
tributing to internal validity is present within societies, and
evenmoresoacrosssocieties.Howwellweareabletocapture
the exposures and the outcomes that we want to assess
is of outmost importance for our results and conclusions.
Physical consequences of cancer and its treatment can be
measures both subjectively and objectively, but perceptions
of physical consequences or psychosocial issues may only
be subjectively reported. The exact relationship between
these diﬀerent types of measures and outcomes has not
yet been established within the ﬁeld of cancer survivorship
research. To what degree these measurements capture what
they aim to, within or across cultures, remains largely
unknown. Because this new research area is in a rush
to ﬁnd results, some studies have performed validation
and reported outcomes simultaneously [52]. It is, however,
important to distinguish “scale validation research” from
studies that attempt to provide information on outcomes
as scale development moves forward [53–55], and it is alsoJournal of Cancer Epidemiology 5
important to clarify the extent to which scales are likely to be
valid across cultures.
To further exemplify, the study of physical late eﬀects
and psychosocial consequences requires monitoring of large
and diverse groups of cancer survivors as the individual
adverse events are relatively rare (i.e., second cancers or
divorce) and occur at various points in time from diagnosis
[25, 26]. Furthermore, some late eﬀects are relevant only
for subgroups of survivors, such as females who received
radiation to the chest area for Non-Hodgkin’s lymphoma
during their reproductive years and later developed breast
cancer. In these instances, cross-cultural studies may enable
a pooling of study subjects and thus provide suﬃcient
power to answer more questions, as has been done in
for instance “The After Breast Cancer Pooling Project”,
established to examine the role of physical activity, adiposity,
dietary factors, supplement use, and quality of life in breast
cancer prognosis among US and Chinese survivors [56]. In
some instances, pooling might preclude study ﬁndings. For
instance could pooling of female cancer survivors’ employ-
ment data from cultures with vastly diﬀerent female employ-
ment patterns yield results that are representative for neither
culture.
In addition, there is a lack of evidence-based guidelines
for whichteststo useand whenfor surveillance,complicating
research measurements. As it is diﬃcult to distinguish eﬀects
of “normal” aging, lifestyle behaviors, and comorbidity from
that related to cancer, comparable control subjects need to
be assessed and followed simultaneously. At present there is a
scarcity of prospectively collected data within most cultures,
which limits the possibility to draw valid conclusions about
causality. On the other hand, prospective studies might
“lock” the data collection to measurement techniques that
become obsolete during the observation period. In addition,
new statistical methods may be needed to account for
sequences of events and the longitudinal nature of late and
long-term eﬀects.
An equally or perhaps more important aspect pertains
to the time span in question. Due to the late onset of
adverse events, information that becomes available is in
many instances the consequences of yesterday’s treatment
regimens, as advances take place and protocols are updated
regularly. The pace may, however, vary across cultures, which
may further hamper comparative research eﬀorts. The infor-
mation obtained may be outdated, although relevant to the
longer-term survivors exposed in the past. New treatments
are often in part based on chemical compounds used earlier,
and although not identical perhaps similar enough that
conclusions may be drawn nonetheless. This has resulted
in an increased focus on the potential role of intermediate
outcomes. With rapid improvements in diagnostic proce-
duresandtreatmentregimens,researchersmustﬁndawayto
develop and utilize intermediate outcomes more frequently.
Sophisticated mathematical modeling can predict outcomes
before they actually occur, and thus allow for appropriate
interventions in advance [57]. Intermediate outcomes may
also help in determining the relative importance of diﬀerent
treatmentregimensversusearlierdiagnosis,helpingtodeter-
mine the value of screening. Cancer survivorship research
thus beneﬁts from multiple measurement techniques and
designs because various research methods have the potential
for providing diverse insights, within as well as across
cultures.
4.3. Challenge III: Avoiding Selection Bias in Initial Partici-
pation and Followup. Previous studies in the ﬁeld of cancer
survivorship have by and large utilized information provided
by aﬀected individuals through interviews or questionnaires.
Unfortunately, response rates have been relatively low and
not representative of the entire population of survivors
[1, 58]. Participation and response rates are in general
related to many of the exposures and outcomes of interest
in cancer survivorship research, and are likely to diﬀer
within and across cultures [27, 28, 58]. In studies based on
membership in groups, organizations, or catchment areas,
further selection bias may be present [59]. Surprisingly,
not all cancer survivors are aware of or accurately report
their diagnosis when asked speciﬁcally to do so [60, 61].
These individuals are unlikely to participate in studies
that are not registry-based and tend to have diﬀerent
characteristics than those who report their diagnosis [60].
Furthermore, similar baseline characteristics among respon-
ders and nonresponders have been shown to be insuﬃcient
evidence of nonresponse bias, as the two groups experi-
ence diﬀerent long-term outcome rates [62]. In general,
participation rates are on the decline today, across studies
a n di nm o s ts o c i e t i e s[ 27, 63]. With high social mobility
in many western countries, many survivors are lost to
followup.
The way research is conducted may create its own barri-
ers. Recent administrative and legal changes across countries
have required studies to have complicated informed consent
[63]. This may increase the potential for bias, as a more com-
plex consent process may make it more likely for healthier,
more resourceful persons to participate [63, 64]. As study
aims and measures become more sophisticated, more precise
answers and more tests may be required from subjects.
This can be time and energy consuming, and persons in
poorer health or those experiencing adverse outcomes may
be less likely to have the ability to participate [27, 64].
Sensitive topics are, in addition, more likely to invoke
diﬀerentialnonresponserates,forinstancesexualpreferences
and/or behavior [65]. Cultural norms and expectations may
inﬂuence both response rates and the information subjects
choose to share. Any or all of the factors listed above limit
our ability to capture complete cohorts. This is unfortunate,
as although the detailed tests, examinations, questionnaires,
and/or interviews may reduce participation, they may at the
same time increase construct validity for those participating.
Achieving a more optimal balance between the two within
a n da c r o s sc u l t u r e si st h u sac h a l l e n g e .
5. Discussion
Cross-cultural comparisons are increasingly important to
maximize the cost-beneﬁt of conducting research without
duplication of eﬀort in cancer survivorship research. These6 Journal of Cancer Epidemiology
comparisons will also help to determine the relative impor-
tance of cultural and societal structures. Although many
consequences of cancer may be culturally dependent, it is
likely that research questions and results may be transferred
to cultures with similar populations, cancer burdens, health
systems,andwelfarestructures.Howtointerpretﬁndingsfor
populations that diﬀer substantially in any of these respects
remains unclear, and culture-speciﬁc research in these areas
remain warranted.
Cancer survivor research encompasses the ﬁelds of
clinical, behavioral, sociologic, anthropologic, economic,
and health services research. We need an increased focus
on genuine interdisciplinary research eﬀorts, where persons
from diﬀerent backgrounds work together in teams to
solve problems, thus coalescing their unique and shared
experiences to create new theoretical and conceptual
models.
The longitudinal nature of cancer survivorship research
remains challenging, as cultures’ rate of uptake of new
detection methods, treatments, as well as research ideas
and methods diﬀer. Current ﬁndings may reﬂect earlier
diagnostic criteria and treatment options and not necessarily
improvements in treatment or “real” changes in other areas.
Methods to simultaneously incorporate aspects of survivor-
ship at individual, group, and societal levels, separately as
wellasjointly,andchangesthatoccurwithinandacrossthese
levels over time are needed.
As populations grow and age so will the number
of cancer survivors, requiring an increased emphasis on
optimal resource management. Reasonable health care costs,
adequate personnel and services, and equal access to care
will be important for both the individual cancer patient and
the greater community. It is thus pertinent that the current
focus on individuals, directly or indirectly aﬀected, shifts to
also include eﬀects at societal levels. In this eﬀort, multilevel
studies will become increasingly relevant.
6. Suggested FutureCourses of Action
We recommend that whenever possible, data should be
made comparable across studies, cultures, regions, and
systems to facilitate larger and more diverse studies and valid
results in universal and speciﬁc contexts. To facilitate this,
cancer registries can expand to include agreed upon factors
important for survivorship as a foundation for prospective
research, nationally and cross-nationally. Further, analytic
tools must be identiﬁed or developed that will enable us to
capture needs of survivors, families, caregivers, clinicians,
health and welfare policy makers and enforcers and also—
taking this a step further—make ﬁndings at group levels
relevant at an individual level for those aﬀected and those
who provide care.
To address the broad aspects of survivorship we need
data, methods, and study designs that can be used to
compare across cultures. Survivorship registries, currently
being developed in Norway, and in Vermont, USA, and
likely other places, will yield important information on
the psychosocial needs and resources, use of diagnostic
tests, treatments received, and risks of recurrences and
morbidities, along with other relevant long-term outcomes
and thus provide a knowledge base for further survivorship
research. In Vermont over 2000 adult cancer survivors
representing nine diﬀerent cancers are available to be invited
into research studies [58]. Basic demographic and cancer
information is known for all the participants. In Norway,
national survivorship registries for prostate and colorectal
cancer which contain information on both initial and
recurrent cancer and treatment have been established at the
Cancer Registry of Norway. These registries may be linked to
several other national registries to obtain for instance cause
of death, medication use, income, education, employment
and marital status. They can also be used to identify patients
to conduct more in depth studies, for example, whether
persons’ quality of life after rectal cancer depend on whether
or not they have a stoma [66].
7. Conclusion
Research hypotheses, questions, and ﬁndings that generalize
to other larger or more diverse populations can be identiﬁed
to increase the rate of new ﬁndings. To optimize data
collection we must strive to increase the comparability across
studies, cultures, regions, and systems to enhance validity in
universal and speciﬁc contexts and thus achieve power to
make valid conclusions also on negative results. The needs of
survivors, families/caregivers, clinicians, health and welfare
policy makers and enforcers can be identiﬁed and addressed
in cross-cultural comparative research. New study designs
and statistical methods will enhance all aspects of cancer
survivorship research. Prioritizing the expansion of cancer
registries to include survivorship data elements will facilitate
prospective research, nationally and cross-culturally. The
relative importance of research that beneﬁts individuals
versus the larger society needs to be assessed, and ﬁndings
at group levels can be made relevant at an individual level
for those aﬀected and those aiming to assist. Our future
lies with interdisciplinary and cross-cultural survivorship
research.
In conclusion, we hope that a comparative perspec-
tive will be considered when new survivorship cohorts
are established and in the planning and implementation
of new survivorship studies. In cancer survivorship care,
research-based knowledge should be applied. Practice must
reciprocally inﬂuence research. In a broader perspective,
cross-cultural comparisons may translate to health and
welfare policy through health services research on cancer
survivorship.
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